Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

BACKGROUND: Aberrant activation of the Hedgehog (Hh) pathway is a key driver in the pathogenesis of basal cell carcinomas (BCCs), including patients with BCC nevus syndrome (BCCNS). It is unclear whether BCCs arising in patients with BCCNS respond differently to vismodegib than in patients without B...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Anne Lynn S., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007799/
https://www.ncbi.nlm.nih.gov/pubmed/27581207
http://dx.doi.org/10.1186/s13023-016-0506-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007799/
https://www.ncbi.nlm.nih.gov/pubmed/27581207
http://dx.doi.org/10.1186/s13023-016-0506-z

Ejemplares similares